Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population

Am J Clin Pathol. 2015 Jan;143(1):126-33. doi: 10.1309/AJCP4Q0NSDHWIZGU.


Objectives: The Xpert HPV Assay (Xpert; Cepheid, Sunnyvale, CA) was developed for the multianalytic GeneXpert platform.

Methods: In a colposcopy referral population of 708 women living in the United States, two cervical specimens, A and B, were collected, and both were tested by the Xpert assay for high-risk human papillomavirus (hrHPV) DNA, permitting an evaluation of its test reliability. Specimen B was also tested by Hybrid Capture 2 (hc2; Qiagen, Germantown, MD) and the cobas HPV Test (cobas; Roche Molecular Systems, Pleasanton, CA).

Results: The κ and percent agreement for any hrHPV for the two Xpert results were 0.88 and 94.5%, respectively. There was no statistical difference in testing positive on both specimens by Xpert (P = .62). The sensitivity for detection of cervical intraepithelial neoplasia grade 2 or more severe (CIN2+) was 89.0% using specimen A and 90.4% using specimen B for Xpert, 90.4% for cobas, and 81.6% for hc2.

Conclusions: The Xpert assay was sensitive and reliable for the detection of hrHPV and the identification of women with CIN2+.

Keywords: Microbiology; Molecular diagnostics; Virology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cervical Intraepithelial Neoplasia / diagnosis*
  • Colposcopy
  • Female
  • Humans
  • Molecular Diagnostic Techniques / methods
  • Papillomavirus Infections / diagnosis*
  • Referral and Consultation
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Uterine Cervical Neoplasms / diagnosis*